Program
taletrectinib
Also written as “Taletrectinib”, “AB-106” and “DS6051b”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nuvation Bio | 105 open or running | phase 3since Aug 12, 2024 | Oct 15, 2014 | Feb 2, 2027phase 1 · NCT07742384 |
| Daiichi Sankyo | 10 open or running | phase 1since Feb 2, 2016 | Feb 2, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 15, 2014First study: phase 1 study in NeoplasmsNew to Nuvation BioNuvation Bio · NCT02279433 · 46 enrolled · United States
- Feb 2, 2016Daiichi Sankyo's first study: phase 1 study in Advanced Solid Malignant TumorsNew to Daiichi SankyoDaiichi Sankyo · NCT02675491 · 15 enrolled · Japan
- May 12, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT04395677 · 173 enrolled · China
- Oct 30, 2020Phase 2 study in Solid TumorNuvation Bio · NCT04617054 · 14 enrolled · China
- May 27, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT04919811 · 217 enrolled · United States, Canada, China and more
- Jul 9, 20212 phase 1 studies in Solid TumorNuvation Bio · NCT05357911, NCT05357820
- Oct 26, 2022Phase 1 study in Pharmacokinetic StudyNuvation Bio · NCT05609929 · 24 enrolled · China
- Aug 12, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT06564324 · 194 planned · China
- Aug 18, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT07154706 · 180 planned · United States, Canada, China
- Jul 13, 2026Phase 1 study in Healthy Adult ParticipantsNuvation Bio · NCT07742384 · 56 planned
Ahead
- Feb 2, 2027Primary completion: phase 1 study in Healthy Adult ParticipantsNuvation Bio · NCT07742384
- Jan 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT06564324
- Aug 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT07154706
TargetBeta
“An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, ”NCIt, by rule
“Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07742384Healthy Adult Participants | 1 | Not yet recruiting | Nuvation Bio | Feb 2, 2027 | 56 |
| NCT07154706Carcinoma, Non-Small-Cell Lung · United States, Canada, China | 3 | Recruiting | Nuvation Bio | Aug 30, 2030 | 180 |
| NCT06564324Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Nuvation Bio | Jan 2029 | 194 |
| NCT05609929Pharmacokinetic Study · China | 1 | Completed | Nuvation Bio | Jan 20, 2023 | 24 |
| NCT05357911Solid Tumor · China | 1 | Completed | Nuvation Bio | Aug 20, 2021 | 16 |
| NCT05357820Solid Tumor · China | 1 | Completed | Nuvation Bio | Dec 3, 2021 | 56 |
| NCT04919811Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more | 2 | Active, not recruiting | Nuvation Bio | Jun 11, 2025 | 217 |
| NCT04617054Solid Tumor · China | 2 | Terminated | Nuvation Bio | Dec 6, 2024 | 14 |
| NCT04395677Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Nuvation Bio | Jun 7, 2024 | 173 |
| NCT02675491Advanced Solid Malignant Tumors · Japan | 1 | Completed | Daiichi Sankyo | Dec 27, 2021 | 15 |
| NCT02279433Neoplasms · United States | 1 | Completed | Nuvation Bio | Mar 2019 | 46 |
How it is read
Names in the registry
- “Taletrectinib”, 5 entries
- “AB-106”, 2 entries
- “DS6051b”, 1 entry
- “DS-6051b”, 1 entry
- “AB-106, Itraconazole”, 1 entry
Codes read as this program: AB106.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.